Completed Access to Information Requests

Follow:

  • RSS
  • Cite
About this information

Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA). For additional information, please see the “About Access to Information Requests” webpage.

If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.

*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.

Download datasets of the summaries of completed access to information requests.

Report Type

Organization

Disposition

Year

Month

Found 62004 record(s)

Req # A-2022-001356

Adverse Drug Reactions (ADRs) for MESALAZINE. Report numbers: E2B_05926116, E2B_05879303, E2B_05951268, 001018724, 001018203, 001018211, 001017894. ADRs for MESALAMINE. Report numbers: E2B_05929118, E2B_05960176. ADR for TEDUGLUTIDE. Report number: E2B_05932422.

Organization: Health Canada

309 page(s)
December 2023

Req # A-2023-000287

Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 23-102700-258.

Organization: Health Canada

29 page(s)
December 2023

Req # A-2023-000422

Adverse Drug Reactions (ADRs). Report numbers: 001038537, E2B_05992367, E2B_06024320, E2B_06286365, E2B_03477995, E2B_03626645.

Organization: Health Canada

115 page(s)
December 2023

Req # A-2023-000462

Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 23-075073-275.

Organization: Health Canada

32 page(s)
December 2023

Req # A-2023-000645

Adverse Drug Reactions (ADRs). Report numbers: E2B_06398091, 001047484, 001039932, 001041436, 001038654, E2B_06371725, E2B_06375154, E2B_06342155, 001042319, E2B_01948466.

Organization: Health Canada

106 page(s)
December 2023

Req # A-2023-000656

Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 23-105904-169.

Organization: Health Canada

41 page(s)
December 2023

Req # A-2023-000675

Adverse Drug Reactions (ADRs) for ZOSTAVAX II. Report numbers: E2B_02229369, E2B_02381693, E2B_02396904, E2B_02504551, E2B_01438894, E2B_02504551, E2B_02381693, E2B_02760591, E2B_02511273, E2B_01497636.

Organization: Health Canada

121 page(s)
December 2023

Req # A-2023-000694

Adverse Drug Reactions (ADRs) for BREXPIPRAZOLE. Report numbers: E2B_06418076, E2B_06419341, E2B_06436667. ADRs for ABILIFY MAINTENA. Report numbers: E2B_06407071, E2B_06432983, E2B_06439726, E2B_06439727, E2B_06441940, E2B_06442211, E2B_06458876.

Organization: Health Canada

172 page(s)
December 2023

Req # A-2023-000700

Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 23-104665-980.

Organization: Health Canada

4 page(s)
December 2023

Req # A-2023-000728

Adverse Drug Reactions (ADRs). Report numbers: E2B_06180779, E2B_06185519, E2B_05360214, E2B_06149321, E2B_06075952, E2B_06089952, E2B_05977659, E2B_06152358, E2B_06151903, E2B_06167563.

Organization: Health Canada

367 page(s)
December 2023
Date modified: